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I N T R O D U C T I O N
Since its initial passage in 1990, the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act
has been critical in ensuring access to HIV care and treatment for hundreds of thousands of persons living
with HIV/AIDS and their families. Today, the CARE Act remains a cornerstone of the Federal effort to fight
HIV/AIDS and continues to provide a critical safety net for over 571,000 individuals affected by HIV/AIDS
who are uninsured or underinsured each year.
With approximately 40,000 new HIV infections each year in the United States, but fewer AIDS deaths (as
the result of remarkable new treatments), more people than ever are living with HIV/AIDS—more people
who need the care and services funded by the CARE Act. Increasingly, these are historically underserved
populations, including racial and ethnic minorities. Responding to these individuals and families, who
depend on the CARE Act for essential health and support services, involves a number of challenges:
+ The ever- i n c reasing cost of health care, particularly the cost of highly active antire t roviral therapy (HAART )
+ An increasing demand on the CARE Act as a primary source for long-term ambulatory and supportive care
+ Changes in the underlying health care financing system that surrounds CARE Act programs.
Each CARE Act reauthorization offers the U.S. Department of Health and Human Services an opportunity
to assess how it can make the CARE Act even more effective at responding to changes in the epidemic and
appropriately targeting resources. These policy studies attempt to improve our understanding of how the
above challenges affect CARE Act programs and the people they serve.
The Health Resources and Services Administration’s (HRSA) HIV/AIDS Bureau is responsible for
implementing the CARE Act. It is in partial fulfillment of this responsibility that the monograph Maximizing
Access to Medications Through Efficient Use of CARE Act Resources is published. The goals for the monograph
are to: expand on current knowledge; inform policy-related, administrative, and legislative decision-mak-
ing; and provide technical assistance to CARE Act grantees and providers that will enhance the quality and
reach of their programs.
This monograph addresses the fact that, given the demands on each CARE Act dollar, grantees must work
even harder to ensure that every possible resource is appropriately directed to provide clients access to treat-
ment, particularly medications. The monograph comprises four policy studies on issues related to the AIDS
Drug Assistance Program (ADAP) Funded under Title II of the CARE Act:
+ Study 1: Factors Contributing to Variations in Per Capita State AIDS Drug Assistance Program Expenditure s
+ Study 2: ADAP Supplemental Funds
+ Study 3: The Role of Title I-Funded AIDS Pharmacy Assistance Programs in Ensuring Access to HIV
Therapeutics
+ Study 4: Issues Associated With Capped Enrollment and Waiting Lists.
Findings and recommendations from these studies will help inform H R SA’s administrative procedures, tech-
nical assistance, and training activities; improve service delivery; and enhance intergovernmental relation-
ships between Federal agencies and among Federal, State, and local jurisdictions. HRSA grantees are
encouraged to read these reports and to incorporate findings and recommendations into their ongoing plan-
ning and program activities.  HRSA welcomes feedback from readers on the usefulness of this monograph
for their work.
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PURPOSE OF THE STUDIES
HRSA’s HIV/AIDS Bureau (HAB) contracted with the George Washington University to conduct a series of
studies regarding various aspects of HIV medications funding through the Ryan White Comprehensive AIDS
Resources Emergency (CARE) Act, including the Title II-funded AIDS Drug Assistance Program and Title I-
funded AIDS Pharmaceutical Assistance Programs. The goal of the studies was to inform HAB regarding (1)
opportunities to promote more efficient use of scarce resources for HIV-related medications and (2) policy
options that might ensure equitable access to life-saving therapies for low-income people living with HIV
(PLWH). The three key issues addressed and the related study questions are shown in Table 1 on page 3.
This report summarizes the methods, limitations, major findings, and recommendations of these studies.
The contents of this report are solely the responsibility of the authors and do not necessarily represent the
official views of HRSA.
STUDY1
FACTORS CONTRIBUTING TO VARIATIONS IN PER CAPITA
STATE AIDS DRUG ASSISTANCE PROGRAM EXPENDITURES
JEFFREY LEVI, JULIA HIDALGO, JOHN PALEN, E. BLAINE
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+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +2
B a c k g ro u n d
State and territorial AIDS Drug Assistance Programs (ADAPs) (referred to in this report as State ADAPs)
report substantial variability in resources for the purchase of HIV medications. Some State ADAPs have
access not only to Title II ADAP earmark and base funds but also Title I and State and local government
funds. Other State ADAPs are entirely funded by ADAP earmark and Title II funds. Some State ADAPs
reportedly have been successful at maximizing their funds through effective cost-containment measures
such as rebate and pricing agreements, retrospective billing to Medicaid, and health insurance purchasing.
State ADAPs also vary in their eligibility criteria and benefits, as well as the extent to which they coordinate
with Medicaid or other payers to ensure that the Ryan White Comprehensive AIDS Resources Emergency
(CARE) Act is the payer of last resort (PLR). 
As a result of the significant variability in State ADAP programmatic design, the per capita expenditures
made by State ADAPs are likely to range widely. Issues of equity have been raised among policy makers, con-
sumers, and advocates. The extent to which per capita expenditures actually vary is unclear, however, as is
the influence of factors associated with that variability. Further analysis is required to obtain this informa-
tion and to identify policy measures that might be adopted to ensure parity in per capita expenditures while
ensuring continued contributions to ADAPs by State and local governments and other funders.
The goal of this project was to inform the HRSA HIV/AIDS Bureau (HAB) regarding the extent to which per
capita State ADAP expenditures vary and the role of various factors in that variation (See Table 1). This study
considered the following factors:
+ Source and amount of non-Federal ADAP funds
+ State ADAP eligibility requirements
+ State ADAP programmatic design, such as mechanisms used to purchase and distribute drugs
+ Covered ADAP benefits, such as the drug formulary
+ Coordination with other funders to ensure that CARE Act funds are used as the PLR
+ Drug payment levels and cost-containment strategies such as negotiated price reductions and rebate
agreements
+ The external health insurance environment that may result in increased or decreased demand for ADAP
enrollment.
M e t h o d o l o g y
Data Sourc e s
All data routinely gathered by the HAB ADAP staff for the period from Federal fiscal year (FY) 1999 through
FY 2003 were reviewed, including the following data sources:
+ State Title II ADAP grant applications for FY 2001 through FY 2003 and ADAP-At-A-Glance tables that
summarize the ADAP State Profiles submitted in the grant applications
+ ADAP Monthly Reports submitted by State ADAPs for January 2001 through June 2003
+ ADAP Quarterly Pricing Reports submitted by State ADAPs for March 2001 through June 2003
+ Calendar year (CY) 2002 ADAP reports submitted by State ADAPs in the CARE Act Data Reports (CADR)
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+ State population-based health insurance enrollment data from the U.S. Bureau of the Census Current
Population Survey (CPS): Annual Social and Economic Supplement obtained from: http:/www.kff.org/
uninsured/upload/29340_1.pdf and published by the Kaiser Commission on Medicaid and the
Uninsured (Health Insurance Coverage in America 2002. Washington, DC: Kaiser Family Foundation,
December 2003) 
+ Follow-up telephone discussions with State ADAP staff to address questions that arose during the course
of the analysis.
George Washington University (GWU) staff analyzed ADAP data to assess timeliness, completeness, and
accuracy. GWU staff also consulted with HAB and State ADAP staff to determine which ADAP databases
should be used in the analyses shown in this report and how to interpret the results.
Computing Per Capita Expenditure s
Annual ADAP State Profile data submitted by State ADAPs were used to calculate the per capita expendi-
tures made by each State ADAP for FY 1999 through FY 2003. Expenditure data submitted by State ADAPs
were actual expenditures for FY 1999 through FY 2002 and estimated expenditures for FY 2003. Total
clients served by the State ADAP were used as the numerator and total expenditures from all sources were
used as the denominator:
Table 1. Key Issues and Related Study Questions
1. State-by-State variability in eligibility criteria and formularies for ADAP
a. What are the geographic variations in client access to State and territorial ADAPs?
b. What are the feasibility and potential impact of establishing a national minimum 
eligibility standard and formulary for ADAPs?
2. Use of ADAP supplemental funds as a vehicle for addressing shortfalls in ADAPs across the
country
a. Why are States not availing themselves of the ADAP supplemental funds?
b. Might different criteria be established to determine need for ADAP supplemental funds?
c. What is the likely impact of reducing the ADAP supplemental match requirement or
modifying the criteria for eligibility for ADAP supplemental funds?
3. HIV medication purchasing under the CARE Act through mechanisms other than ADAPs
a. How do these programs coordinate with ADAPs?
b. Have these programs negotiated price discounts similar to those negotiated by ADAPs?
c. Do these programs determine eligibility for non-CARE Act programs before paying for
drugs for their CARE Act clients?
Annual State ADAP
per capita expenditure s
Total number of ADAP clients serv e d
Total ADAP expenditures from all sourc e s
=
Total ADAP expenditures, regardless of the funding source, were summed for each year to calculate the
denominator. Sources of expenditures included Title II ADAP earmark funds, Title II base funds, Title I
funds allocated to the State ADAP, State ADAP matching funds, other State revenue, other local funds, and
other sources of funds. State ADAP per capita annual expenditures were used as the unit of analysis. State
ADAP expenditure data included purchases made for the following five types of services:
1. Medications (including the price of individual medications and the dispensing fee)
2. Health insurance premiums
3. Health insurance deductibles
4. Health insurance co-payments
5. Flexibility policy expenditures for adherence and monitoring related to ADAP clients.
Per capita expenditures were calculated for each State ADAP for a 3-year period covering FY 2001, FY 2002,
and FY 2003. State ADAP eligibility, coverage, cost-containment, Medicaid program coordination, and other
relevant programmatic characteristics were appended to the per capita expenditure data for each State ADAP
and fiscal year studied. Additional health insurance coverage data from the CPS were obtained for CY 2002,
the most recent calendar year available. In the absence of trend data, individual State CY 2002 CPS data
were used as a constant variable for CY 2001 and CY 2003.
L i m i t a t i o n s
Computations of per capita expenditures did not include adjustments for inflation for the period in which
this analysis was conducted. Inflation is likely to have some impact on the “real dollars” available to State
ADAPs to purchase medications and health insurance premiums, deductibles, and co-payments. Because of
the absence of State ADAP data regarding medication-specific and health insurance–related expenditures, it
was not possible to identify medical market inflation data that closely mirrors the unique and varied bene-
fit packages supported by the State ADAPs. 
Pricing data submitted to HAB could not be used for this analysis. The pricing data apparently include med-
ication purchases as well as co-payments and deductibles in the pricing data for pharmaceuticals purchased
by individual ADAPs. 
GWU staff encountered several challenges in assessing the factors associated with differences in per capita
expenditures. Specific data issues that were identified and explored with HAB staff included the following:
+ I n t e rviews with State ADAP staff indicated that they may interpret HAB data collection forms diff e re n t l y.
+ Per capita ADAP expenditure data available from HAB most directly measure medication purchasing and
not the other services funded with ADAP dollars.
+ Some State ADAPs have not submitted all required forms, have not completed sections of some forms,
or have submitted their “best guesses.” For example, 28 percent of State ADAPs did not submit total
expenditure data in their CY 2002 ADAP CADRs. As a result, GWU staff could not use CADR data as
part of this analysis.
+ Person-based expenditure data are not available to HAB for accurately computing the actual expendi-
tures for the various types of services purchased. Despite substantial variability in the length of enroll-
ment by clients in State ADAPs, the ADAPs do not report the data to HAB. Person-based data also are
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not available to differentiate among per capita expenditures made for deductibles, co-payments, health
insurance premiums, or medication purchases.
+ Because of the lack of available data, GWU cannot assess the contribution of carryover ADAP earmark
and Title II base funds to variable per capita expenditures. Several State ADAPs are reported by HAB staff
to have carried over large amounts of ADAP earmark funds but it is unclear what impact those funds
have had on per capita ADAP expenditures.
+ Incomplete pricing data hinders our ability to assess the direct relationship between pricing and per
capita expenditures. In reviewing pricing data with HAB staff, it was concluded that pricing data were
included in the price of co-payments and deductibles as well as in the actual average price of the med-
ications purchased by State ADAPs. Variability in pricing by State ADAPs is not adequately captured by
current data collection mechanisms.
+ Given these various challenges, only estimated per capita annual ADAP expenditures are feasible at
this time.
Major Findings
Trends in ADAP Enrollment and Expenditures That Affect Per Capita Expenditure s
Demand for ADAP services increased sharply during the late 1990s with the adoption of highly active
a n t i re t roviral therapy (HAART) by clinicians treating HIV-infected patients and with the growth in the
number of HIV-infected patients without other pharmaceutical coverage. By FY 2003, a total of 151,304
clients were receiving one or more ADAP-funded services annually. Annual total enrollment varied gre a t l y
among State ADAPs. For example, an average of 2,855 clients enrolled in State ADAPs in FY 2003, but
e n rollment ranged from 8 clients in Guam to 24,534 clients in California. State ADAPs re p o rted that vari-
ability in enrollment significantly influences their ability to negotiate rebates and effectively use other cost-
containment mechanisms.
The average number of clients enrolled in State ADAPs rose from 2,049 in FY 1999 to 2,922 in FY 2002.
Average enrollment then dropped to 2,855 clients in FY 2003. The rate of change in average annual State
ADAP enrollment between fiscal years was 18.3 percent between FY 1999 and FY 2000; 8.7 percent between
FY 2000 and FY 2001; 10.8 percent between FY 2001 and FY 2002; and -2.3 percent between FY 2002 and
FY 2003. The plateau of State ADAP enrollment may be attributable to several factors, including a flatten-
ing in the rate of newly identified HIV-infected individuals seeking enrollment, capping of State ADAP
enrollment, and implementation of waiting lists because of inadequate funding.
Several State ADAPs account for the most enrollees. Ten State ADAPs accounted for 73 percent of total
enrollment in FY 2003: California accounted for 17 percent of enrollment; New York had 15 percent of
enrollment; Florida, 11 percent; Texas, 8 percent; Puerto Rico, 7 percent; New Jersey, 4 percent;
Pennsylvania, 3 percent; Illinois, 3 percent, Georgia, 3 percent; and Washington, 2 percent. All other State
ADAPs accounted for 27 percent of national ADAP enrollment. 
State ADAP expenditures are based on ADAP earmark and Title II funds as well as other sources of CARE
Act and non-Federal funding. National ADAP expenditures rose 10 percent between FY 1999 and FY 2000,
10 percent between FY 2000 and FY 2001, 11 percent between FY 2001 and FY 2002, and 9 percent
between FY 2002 and FY 2003. By FY 2003, ADAP expenditures totaled more than $1 billion. 
Title II earmark funds represented 66.7 percent of total ADAP funds expended. Title II supplemental funds
accounted for 2.1 percent; Title II base funds, 2.3 percent; Title I funds, 2.2 percent; ADAP State matching
funds, 0.5 percent; other State funds, 15.5 percent; and other funds, 10.8 percent. City and county revenue
made up most of these other funds. State ADAPs vary substantially in the array of funding streams used to
support their programs. Of the 57 State ADAPs funded in FY 2003, 42 State ADAPs (73.7 percent) did not
receive Title I funds; 18 State ADAPs (31.6 percent) received no State non-matching funds; and 26 State
ADAPs (45.6 percent) received no other funds, such as city or county revenue. All State ADAPs received
ADAP earmarked funds.
Other State funds, excluding revenue used for the ADAP match requirement of the CARE Act, were an
important source of State ADAP support between FY 1999 and FY 2003. Nonmatching State funds fluctu-
ated slightly between FY 2001 and FY 2003: 47.6 percent, 45.6 percent, and 46.4 percent (respectively) of
nonearmark State ADAP funds came from State revenue. Other funds, including city and county revenue,
were also an important and growing source of State ADAP funds during this period. The percentage of State
ADAP nonearmark funds derived from other sources rose from 27.8 percent in FY 2001 to 28.0 percent in
FY 2002 and to 32.4 percent in FY 2003. 
Following the trends in enrollment, 10 State ADAP expenditures accounted for 72 percent of total expen-
ditures. New York, California, and Florida alone accounted for 45 percent of State ADAP expenditures. On
average, ADAP expenditures rose per State from $13.4 million in FY 1999 to $19.2 million in FY 2003. The
average expenditures across State ADAPs, however, obscure the substantial range in actual expenditures
among State ADAPs. In FY 2003, for example, total expenditures per State ADAP varied from $91,319 to
$200.8 million, reflecting differences in the amounts and sources of funds that support those programs.
Analysis of the trends in average State ADAP expenditures indicated relatively steady growth in average
expenditures by State ADAPs between FY 1999 and FY 2002, with the rate of increase in expenditures aver-
aging 9.9 percent between FY 1999 and FY 2000, 10.2 percent between FY 2000 and FY 2001, and 14.8
percent between FY 2001 and FY 2002. The trend in increased growth in expenditures changed between FY
2002 and FY 2003, with the increase in expenditures dropping to 3.3 percent. In actual dollars, the aver-
age increase in State ADAP expenditures was $1.3 million between FY 1999 and FY 2000, $1.5 million
between FY 2000 and FY 2001, $2.4 million between FY 2001 and FY 2002, and $616,792 in FY 2003. A
slight but steady increase was observed in the average expenditures of State ADAPs between FY 1999 and
2003. These underlying numeric distributional characteristics of expenditures, along with expenditure pat-
terns among some State ADAPs, resulted in the difference between average expenditures among State ADAPs
over time being not statistically significant.
Per Capita Expenditure s
Trends were identified in State ADAP per capita expenditures among State ADAPs. Annual total per capita
expenditures varied greatly among State ADAPs during the period studied. In FY 2003, for example, total
per capita expenditures per State ADAP varied from $1,583 to $23,304. This variability reflects differences
in the size of the enrollments in State ADAPs as well as in the amount and sources of funds supporting those
programs. The median per capita expenditures, less likely to be influenced by outlier data, rose from $5,853
in FY 1999 to $6,446 in FY 2000 and $6,752 in FY 2001. Median per capita expenditures then decreased
to $6,604 in FY 2002 and rose again to $7,099 in FY 2003. 
Analysis of the trends in average State ADAP per capita expenditures indicated that average per capita expen-
ditures by State ADAPs dropped 0.6 percent between FY 1999 and FY 2000 and then rose 1.5 percent
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between FY 2000 and FY 2001, 1.9 percent between FY 2001 and FY 2002, and 12.0 percent between FY
2001 and FY 2002. Reportedly inaccurate data submitted by one State ADAP skewed FY 2003 per capita
expenditure data. When those data were removed from the analysis, the average per capita expenditure
between FY 2002 and FY 2003 rose 7.5 percent. 
In actual dollars, average State ADAP per capita expenditures dropped $40 between FY 1999 and FY 2000
and then rose $97 between FY 2000 and FY 2001, $126 between FY 2001 and FY 2002, and $493 in FY
2003 (deleting the inaccurate outlier for FY 2003). Using both parametric and nonparametric measures to
assess differences between the mean and median per capita expenditures, no statistically significant differ-
ences were identified. Note that although no statistically significant differences in per capita expenditures
were found, any incremental increase in expenditures has an impact on ADAP clients’ buying power.
Trends in per capita State ADAP expenditures were examined for the top 10 and bottom 10 States and ter-
ritories for FYs 2001, 2002, and 2003. In FY 2003, for example, per capita expenditures were reported to
be highest in Tennessee ($23,304), followed by Indiana ($13,120), Maryland ($12,020), Massachusetts
($11,695), Guam ($11,415), Michigan ($11,357), Ohio ($10,988), Delaware ($10,869), Maine ($10,765),
and Oregon ($10,418). These States and territories vary substantially in enrollment, total funds expended,
sources of ADAP funding (including total Title I funds allocated), eligibility requirements, formulary, and
payment for insurance-related expenses. Note that the per capita expenditures reported in FY 2003 for
Tennessee are likely to be in error as a result of data quality issues.
The States and territories with the lowest per capita ADAP expenditures were also computed. In FY 2003, for
example, per capita expenditures were re p o rted to be lowest in Wyoming ($1,583), Puerto Rico ($2,691),
Washington ($3,150), New Mexico ($3,222), Kansas ($3,409), Nebraska ($3,559), Minnesota ($4,136),
N o rth Dakota ($4,488), the U.S. Vi rgin Islands ($4,488), and Missouri ($4,764). These States and terr i t o r i e s
also vary widely in enrollment, total funds expended, sources of ADAP funding (including total Title I funds
allocated), eligibility re q u i rements, form u l a ry, and payment for insurance-related expenses. Some of these
States and territories have been able to reduce their per capita expenditures because they purchase insurance
p remiums for medications and other health care benefits. Other States and territories with low per capita
e x p e n d i t u res have relatively small ADAP budgets that are dedicated primarily to medication purc h a s i n g .
Factors Contributing to Variation in ADAP Per Capita Expenditure s
GWU explored the association between ADAP per capita expenditures and geographic location, State ADAP
characteristics, the characteristics of Medicaid programs in the States in which the ADAPs operate, and the
e x t e rnal State health care environment. Table 2 (see page 9) outlines those factors. A significant, negative asso-
ciation was found to exist between State per capita expenditures and the total co-payments and deductibles
paid per year by State ADAPs. The higher the per capita State ADAP expenditures, the lower the total co-
payments and deductibles paid per year by State ADAPs. Conversely, the higher the per capita State ADAP
e x p e n d i t u res per year, the lower the percentage of the State population with individual commercial insurance. 
Results of statistical analyses underscore the importance of a close collaborative relationship between State
ADAPs and the Medicaid program to ensure that people eligible for Medicaid benefits rapidly enroll in that
program. State ADAP per capita expenditures were lower among programs that had a Medicaid online inter-
face with which Medicaid enrollment could be verified ($6,617) than among State ADAPs that did not have
this interface ($7,862). Note that several large and medium-sized State ADAPs still do not have an electronic
interface in place because of technical issues or lack of interagency agreement about the feasibility or legality
of such an interface. State ADAP per capita expenditures were higher among programs with dual
applications for Medicaid and ADAP enrollment ($8,281) than among State ADAPs without dual applica-
tions ($6,649). State ADAP per capita expenditures were higher among programs requiring proof of
Medicaid application denial ($7,758) than among State ADAPs without this requirement ($6,411). A non-
significant weak association was found between State ADAP per capita expenditures and joint ADAP and
Medicaid administration at the State level; States with joint administration had lower average per capita
expenditures ($5,828) than State ADAPs without joint administration ($7,188). 
Statistical analysis also pointed to the importance of State ADAPs retroactively billing Medicaid for ADAP
clients that are subsequently awarded retroactive Medicaid pharmaceutical coverage. State ADAP per capita
expenditures were lower among programs with retroactive Medicaid billing ($6,041) than among State
ADAPs that did not have this billing process ($7,808).
GWU staff explored the relationship between per capita State ADAP expenditures and receipt of Title I
funds. In FY 2003, 12 States or territories (22 percent of State ADAPs) reported receiving Title I funds. In
FY 2003, Title I funds received by State ADAPs ranged from $57,425 to $18 million and averaged $426,924.
The number of State ADAPs receiving Title I funds increased between FY 2002 and FY 2003, with 12 State
ADAPs receiving Title I funds in FY 2003, compared with 8 State ADAPs in FY 2002. The average per capi-
ta amount was $8,359 for States receiving Title I funds, compared with $7,125 for States that did not receive
Title I funds. This difference was not statistically significant, however.
D i s c u s s i o n
While conducting this study, State ADAPs continued to make rapid changes in their program designs and
policies that were not reflected in the data available to GWU staff, including the following:
+ Setting further limits on income and assets
+ Adjusting the frequency of recertification (monthly, quarterly, biannually, or annually, as the formulary
was changed)
+ Requiring Medicaid application or proof of denial
+ Establishing online interface with Medicaid to reduce dual enrollment
+ Increasing assessment of case management eligibility 
+ Denying benefits to veterans
+ Establishing waiting lists and capped enrollment
+ Prioritizing applicants on the basis of clinical factors (pregnancy, CD4, or viral load)
+ Reducing the formulary to exclude drugs not directly related to HIV treatment
+ Establishing a monthly ceiling on the number of drugs paid for by the State ADAP
+ Setting limits on protease inhibitors (PIs) or opportunistic infection medications
+ Attempting to expand rebate agreements and reduced prices
+ Establishing co-payments for ADAP clients
+ Increasing the purchase of insurance premiums
+ Reorganizing distribution systems to reduce dispensing costs
+ Implementing retrospective Medicaid billing.
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Table 2. Factors Associated With Variable State ADAP Per Capita
E x p e n d i t u re s
+ Geographic variations based on State ADAP-specific data
+ ADAP demand for services as measured by State ADAP enrollment trends
+ ADAP financial resources associated with the various types of CARE Act and non-
CARE Act funding streams used to support the State ADAPs
+ Whether the ADAP Flexibility Policy has been adopted by the State ADAPs
+ The ADAP formulary, including the total number of drugs in the formulary, the total
number of antiretroviral drugs (ARVs), and the total number of protease inhibitors 
+ Financial eligibility of ADAP clients
+ Coordination of ADAP with Medicaid, including co-management of the Medicaid and
ADAP programs, access by State ADAP staff to online Medicaid eligibility verification
system records
+ The ADAP cost-containment strategy, including rebates and pricing agreements
+ The health insurance environment affecting ADAP enrollment, including the perc e n t a g e
of the State population enrolled in private insurance or Medicaid and the perc e n t a g e
u n i n s u re d
+ Health insurance benefits purchased by ADAP, including health insurance premiums,
coverage of co-payments, and coverage of deductibles
+ Resource requirements of ADAP clients based on trends in enrollment in FYs 2001,
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B a c k g ro u n d
The ADAP supplemental funds allocated in FY 2003 amounted to $21 million, or 3 percent of the total
amount allocated to the CARE Act ADAP earmark budget. ADAP supplemental funds are meant to assist the
States that are most challenged in supporting their ADAP. Not all eligible State ADAPs, however, have accessed
supplemental funds. ADAP supplemental funds target jurisdictions that met specific qualifications as of
J a n u a ry 1, 2000. Only States that met at least one of the following criteria on that date are eligible to apply:
+ Financial eligibility restriction to less than or equal to 200 percent of Federal Poverty Level (FPL)
+ Medical eligibility restrictions
+ Limited formulary composition for antiretroviral drugs (ARVs)
+ Limited formulary compositions (fewer than 10 medications) for the treatment of opportunistic
infections.
States are also required to match the Federal supplement award at a rate of one State dollar for every four
Federal dollars. The CARE Act requires that States receiving ADAP supplemental funds maintain their cur-
rent levels of effort in their ADAP funding. In FY 2003, 27 States and territories were eligible to apply for
ADAP supplemental funds. Of those jurisdictions, 17 received ADAP supplemental funding: Alabama,
Colorado, Georgia, Guam, Idaho, Kentucky, Louisiana, Nebraska, North Carolina, Oklahoma, Puerto Rico,
South Carolina, Texas, Virgin Islands, Virginia, West Virginia, and Wisconsin. States that were eligible based
on FY 2000 criteria butdid not apply included Alaska, Arizona, Iowa, Maine, Montana, North Dakota, South
Dakota, Tennessee, Utah, and Vermont.
HAB requested that GWU staff collect information about the following topics: 
+ Why States are not availing themselves of ADAP supplemental funds
+ Whether different criteria might be established to determine need for ADAP supplemental funds 
+ The likely impact of reducing the ADAP supplemental match requirement or modifying the eligibility
criteria for ADAP supplemental funds.
M e t h o d o l o g y
In a separate study sponsored by HAB, Positive Outcomes, Inc. (POI) staff interviewed ADAP coordinators
in States that met the FY 2000 criteria for ADAP supplemental funds but did not request them. Under an
agreement with HAB, POI provided interview notes to GWU staff to assist in this study. Additional infor-
mation gathered by GWU staff included information gathered from HAB, the National Alliance of State and
Territorial AIDS Directors, and the CARE Act legislation. The following information reflects a synthesis of
those data.
L i m i t a t i o n s
No limitations were identified in conducting this study. State ADAP staff was very cooperative with study staff .
Major Findings
Why are States not availing themselves of the ADAP supplemental funds? 
+ The State ADAP supplemental match requirement is the most difficult hurdle to overcome. State ADAPs
reported that neither direct matching funds for ADAP nor in-kind resources used to support the match
are available in a time of tight State budgets. 
+ Some State ADAP coordinators reported that because the ADAP supplemental funds are not stable and
there is no guarantee of future funding, they are concerned that they might increase enrollment in one
year based on newly awarded supplemental funds only to have to disenroll clients the next year because
of inadequate funds. 
+ Several State ADAPs are not willing to change their eligibility re q u i rements (e.g., financial, medical re s t r i c-
tions, limited form u l a ry) to receive supplemental funding. In some States, eligibility re q u i rements must
be established by the State legislature. Without pre-identified Federal funds to support expanded enro l l-
ment or benefits, State legislators are unwilling to make changes in ADAPs that might re q u i re State funds.
Would the establishment of different criteria improve the participation of States or the effectiveness of the ADAP sup-
plemental program?
+ Needs-based distribution of ADAP supplemental funds could influence the impact of these funds as well
as State participation. Using needs-based distribution of supplemental funds would take into consider-
ation the uniqueness of each State’s needs. Several ADAP coordinators commented that their request for
ADAP supplemental funds was far short of their projected requirements. They also commented that sev-
eral other State ADAPs received more supplemental funds than they had requested. 
+ State ADAP coordinators indicated that multiyear, guaranteed minimum funding would make them
more likely to apply for ADAP supplemental funds. 
What are the likely effects of reducing the ADAP match requirement or modifying the eligibility criteria for supple-
mental funding?
+ State ADAPs reported that slightly modifying the match requirement will have little impact because State
budget crises currently preclude allocation of any State matching funds. 
+ Modification of the eligibility criteria was not seen as removing as significant a barrier to accessing sup-
plemental funds as the State ADAP match requirement. Criteria such as a financial eligibility restriction
of 200 percent of FPL or lower, medical eligibility restrictions, limited formulary composition for ARVs,
and limited formulary compositions were not seen as being as immutable a barrier as the State match. 
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B a c k g ro u n d
Many communities are encountering constrained public funding due to decreased tax revenue and increased
expenditures for Medicaid and other entitlement programs. As a result, Medicaid and State-funded health
insurance pools and pharmacy programs have reduced or eliminated benefits for medically needy adults,
including people living with HIV (PLWH). At the same time, many State ADAPs have narrowed their eligi-
bility criteria and decreased benefits to contain costs. 
Changes in indigent care programs and the growing number of newly identified HIV-infected individuals
have resulted in significant growth in the number of uninsured and underinsured PLWH in many commu-
nities. Concurrently, new HIV medications continue to be approved by the Food and Drug Administration
(FDA), and new combinations of therapeutics are being introduced into HIV medical practice. These forces
are likely to prompt either steady or increased demand for HIV medications in the near future.
These factors make the role of Title I–funded AIDS Pharmacy Assistance (APA) programs increasingly
important in ensuring that HIV medications are accessible and affordable. In FY 2002 alone, Title I Eligible
Metropolitan Areas (EMAs) allocated almost $40 million to APAs. APA expenditures represented 6 percent
of total Title I funds in FYs 1999 and 2000; 9 percent in FY 2001; and 6 percent in FY 2002. Despite the
large financial outlays made by Title I APAs, little is known about their design. Moreover, it is unclear how
APAs coordinate eligibility and benefits with State ADAPs, Medicaid, the Department of Veterans Affairs
(VA), and other payers to ensure optimal use of public funds. 
The goal of this study was to help HAB identify and maximize resources available to support HIV medica-
tion costs by
+ Gaining a better understanding of the role of APAs in ensuring access to HIV medications;
+ Identifying the distinction and overlap between APAs and ADAPs;
+ Evaluating the extent to which APAs coordinate benefits with ADAPs, Medicaid, and other payers; and
+ Assessing the extent to which APAs maximize their resources.
M e t h o d o l o g y
GWU staff conducted a voluntary, email-based survey of Title I grantees that fund APAs. Before conducting
the survey, an institutional review board (IRB) package was prepared and submitted to the GWU IRB for
review. Approval was granted, and a copy of the survey and accompanying IRB materials were sent to the
Title I grantees that HAB had identified as having an APA. The survey was in the field from February 2004
through March 2004, and a total of 21 Title I grantees with APAs were contacted. The Title I grantees
received an initial email requesting that they complete the survey. Nonresponding grantees received several
email reminders and one telephone reminder call. One Title I grantee (Denver) reported that it no longer
operated an APA. Of the remaining 20 Title I grantees listed in Table 3, 17 (85 percent) responded. The three
nonresponding APAs were located in moderate-size EMAs in California, Puerto Rico, and Texas.
L i m i t a t i o n s
Three EMAs did not respond to the survey. It is unclear to what extent the characteristics of their APAs differ
from APAs of responding EMAs. Several EMAs did not provide a copy of their formularies.
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Major Findings
A PA Eligibility Require m e n t s
Less than one-third (29 percent) of the responding APAs re p o rted using centralized eligibility determ i n a t i o n ,
w h e reas two APAs (12 percent) use decentralized eligibility through community-based case managers. The
remaining APAs did not provide data on their processes for determining eligibility. Seventy-one percent of the
A PAs have a county residency re q u i rement. Of the 12 APAs with a residency re q u i rement, 4 (23 perc e n t )
re q u i re that an applicant reside in the county for at least 1 month; 1 (6 percent) re q u i re a 12-month re s i-
dency; and the remainder did not re p o rt the length of their residency re q u i rement. Only two APAs (12 per-
cent) re p o rted having a clinical re q u i rement, such as CD4 count or viral load, to be enrolled in the pro g r a m .
Redetermination of APA eligibility varies among APAs. Of the 17 APAs responding to the survey, 1 (6 per-
cent) requires quarterly redetermination; 7 (42 percent) require redetermination every 6 months; 8 (47 per-
cent) require annual redetermination, and 1 (6 percent) requires redetermination in the event of a significant
change in income or other eligibility criterion. 
Income and documentation requirements of APAs also vary. Most of the APAs surveyed (88 percent) require
proof of income; only two (12 percent) reported that proof of income is not required. Five APAs (29 per-
cent) reported having no income requirement. One APA (6 percent) has a maximum allowable income of
199 percent of the FPL; 7 (41 percent) set the ceiling at 299 percent of FPL; 2 (12 percent) set the ceiling
at 399 percent of FPL; and 2 (12 percent) set the ceiling at 499 percent of FPL. In a separate survey item,
however, 10 APAs (59 percent) reported that they do not have an income ceiling. More than one-half of the
APAs (59 percent) require that applicants apply for Medicaid concurrently with the application for assistance
from the APA. Only about one-quarter of the APAs (23 percent), however, require that applicants show proof
of Medicaid denial to be eligible for APA enrollment. Veterans are eligible to enroll in slightly more than one-
half of the responding APAs (59 percent). In most APAs (88 percent), clients also are allowed to enroll in a
State ADAP.
Table 3. Title I Eligible Metropolitan Areas That Fund AIDS Pharmacy Assistance Programs
Atlanta, GA Orange County, CA
Caguas, PR* Patterson, NJ
Cleveland, OH Phoenix, AZ
Dallas, TX Saint Louis, MO 
Fort Lauderdale/Broward County, FL San Antonio, TX*
Fort Worth/Tarrant County, TX San Bernardino/Riverside, CA
Houston, TX San Diego, CA
Jacksonville, FL Santa Clara County, CA
Miami, FL Tampa, FL
New Orleans, LA West Palm Beach/Palm Beach County, FL
* Nonresponding EMAs
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A PA Covered Benefits
Among the 17 responding APAs, all purchase medications with Title I funds. Two of the 17 APAs also pur-
chase insurance premiums, and 6 reported paying co-payments on behalf of clients. GWU asked Title I APAs
to include a copy of their formulary with their completed survey form. Twelve APAs provided a copy of their
current formulary. The submitted APA formularies vary substantially, and many APAs include HIV medica-
tions that are also covered by their State’s Medicaid program and ADAP. Additionally, the APAs tend to have
formularies that are broader than their State ADAP to compensate for medications required to treat HIV and
non-HIV-related conditions common among PLWH. In addition to prescribed medications, some APAs
cover over-the-counter medications and medical supplies. APAs tended to report somewhat similar patterns
of coverage of HIV antiretrovirals (ARVs). The number of ARVs covered by APAs ranged from 8 ARVs
(Patterson, NJ) to 21 (Fort Lauderdale, FL); the modal number of ARVs covered was 20. Only 2 of the 12
APAs that submitted their formularies to GWU covered Fuzeon.
Relationship of APAs to ADAPs
The effective coordination of eligibility and coverage policies between APAs and ADAPs is important given
the high number of APA clients that can also enroll in a State ADAP. While 88 percent of APAs allow their
clients to enroll in a State ADAP, only 41 percent of the EMAs with APAs allocate funds to their State ADAPs.
Two of the 17 APAs reported that their State ADAPs do not need Title I funds. Some APAs reported that their
role is to provide benefits that wrap around those covered by the State ADAP. Almost all the APAs (94 per-
cent) covered drugs not covered by ADAP. About one-third of APAs (35 percent) cover clients not eligible
for ADAP, whereas almost one-quarter (23 percent) enroll ADAP-disenrolled clients. Despite the importance
of coordination of benefits with ADAPs, only about one-third of APAs (35 percent) reported coordinating
coverage of newly approved HIV drugs with their State ADAPs. Only 29 percent of APAs reported coordi-
nating the benefits of individual clients.
Relationship of APAs to Medicaid
Reflecting the importance of coordinating APA eligibility with the Medicaid Program, almost three-quarters
of APAs (71 percent) reported having access to electronic Medicaid eligibility records. It is unclear, however,
how often those records are reviewed to identify newly enrolled or disenrolled Medicaid beneficiaries. Most
APAs (82 percent) reported covering clients who are not Medicaid eligible, and more than one-half (59 per-
cent) cover Medicaid beneficiaries. Reflecting the highly restrictive coverage of the Texas Medicaid Program,
the APAs located in Texas reported enrolling Medicaid beneficiaries. As with State ADAPs, some APAs func-
tion as a wraparound for Medicaid benefits: almost one-third of APAs (29 percent) cover medications that
are not on Medicaid’s formulary.
A PA Cost-Containment Mechanisms
APAs reported using a variety of cost-containment strategies. As mentioned earlier, two APAs (12 percent)
purchase health insurance premiums. About two-thirds of APAs (65 percent) have Section 340B direct pur-
chase arrangements, whereas one APA (6 percent) participates in the 340B rebate program. Only three APAs
(18 percent) reported having negotiated price reductions with manufacturers. It is unclear, however, how
many of the drugs on these APAs’ formularies were purchased on a price-reduction basis. Only four APAs
(23 percent) reported having negotiated dispensing fee or other price reductions from retail or mail-order
pharmacies. Use of manufacturers’ patient assistance programs is uncommon among APAs: only six (35 per-
cent) reported such referrals. Other cost-containment strategies that are used by APAs are likely to reduce
access to HIV medications. Two APAs (12 percent) limit the number of clients that can enroll in the APA.
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Almost one-half of APAs (47 percent) reported limiting the number of drugs on their formulary, and 18 per-
cent of APAs reported limiting the number of prescriptions per client. Forty-one percent limit the number
of dispensing pharmacies with which they contract. It does not appear that APAs follow the CARE Act’s
requirement that a sliding fee scale be used to determine the amount of co-payment required from the APA
and other clients. No APA reported requiring clients to pay a co-payment. Because of limits on the number
of clients that can enroll in an APA, one APA reported having had a waiting list for 12 months at the time
the survey was conducted; another APA had had a waiting list for 4 months, and a third APA had had a
waiting list for 2 months.
Benefits of APA Funding Reported by EMAs
GWU asked Title I grantees to comment on the benefits of APAs to their EMAs. Respondents reported the
following benefits to funding an APA: 
+ A PAs are viewed as a stopgap measure while clients await ADAP or Medicaid enro l l m e n t .
+ In some EMAs, APAs purchase medications at specific points of care to ensure that they are immediately
available. As a result, filling prescriptions is convenient to clients and the system ensures that pre s c r i p t i o n s
a re filled on a timely basis.
+ A PA funds are used to reduce co-payments that would otherwise act as a barrier to access to pharm a c e u-
t i c a l s .
+ The APA formularies are broader than those available from some Medicaid programs (e.g., Texas) or State
A D A P s .
+ Several respondents indicated that APAs are cost-effective, although no formal studies of their cost-
e ffectiveness were off e red by APAs to support this claim.
+ Several Title I grantees re p o rted that the APAs in their EMAs function as the PLR because no other
p rograms will provide pharmaceutical coverage to their clients.
Disadvantages of APA Funding Reported by EMAs
Title I grantees also commented on the following disadvantages of APAs to their EMAs:
+ APAs are labor intensive and have burdensome administrative functions. As a result, Title I grantees
must absorb the cost of administering the APAs.
+ Several APAs commented that they have limited distribution systems that result in reduced access to
retail pharmacies.
+ APAs reported that it is difficult to coordinate benefits with other payers. Data-sharing issues related to
client confidentiality are frequent because other payers will not accept APA patient-release forms.
+ Despite the importance of recertification to ensure that APA clients are appropriately enrolled, frequent
recertification was reported to be a burden for clients.
+ Cost-containment was reported to be a challenge for many APAs because they lack the buying power of
State ADAPs and the ability to negotiate pricing and rebate agreements.
+ As resources decrease in other systems (e.g., ADAPs, the Health Insurance Continuation Program,
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B a c k g ro u n d
Through the CARE Act, HRSA’s HIV/AIDS Bureau (HAB) provides funding to States and U.S. territories to
administer the AIDS Drug Assistance Program (ADAP). Over the past several years, ADAPs have experienced
insufficient funds to support growing enrollment, increased expenditures, and lengthened enrollment peri-
ods. To deal with those difficulties, ADAPs have instituted a variety of cost-containment measures, includ-
ing capped enrollment and waiting lists. 
The purpose of this assessment was to identify ADAP policies and procedures developed by States to guide
ADAP staff in implementing and operating capped enrollment programs, waiting lists, or both.
State ADAPs Participating in the Assessment
+ State ADAPs with Waiting Lists or Capped Enrollment
Alabama, Arkansas, Idaho, Iowa, Kentucky, Montana, North Carolina, Oklahoma, South Dakota,
and West Virginia
+ States Anticipating Waiting Lists and/or Capped Enrollment
Massachusetts, Missouri, and New Mexico
+ States with Capped Enrollment or Waiting Lists Not Participating in the Assessment
Alaska and Colorado
M e t h o d o l o g y
GWU researchers interviewed the ADAP administrators of 14 States. Eleven States reported using capped
enrollment: Alabama had set its cap at 1,232; Arkansas, at 460; and Idaho, at 109. Kentucky had a rolling
cap, as did Montana and North Carolina. South Dakota had set its cap at 70, and West Virginia at 200. Iowa,
which had 210 clients, but needed to limit the program to 135 to 165 clients but had not officially set a cap.
Indiana had set a cap of 1,250 but was just approaching the cap. Oklahoma had set a monetary cap of
$1,200 per client per month, but was just reaching that amount. Three additional States—Massachusetts,
Missouri, and New Mexico—reported that they anticipated capping enrollments or instituting a waiting list
in the near future.
Eight States reported having waiting lists. Alabama had 391 people on the waiting list at the time of the
study. Idaho had 17; Iowa, 16; Kentucky, 18; Montana, 8; North Carolina, 774; South Dakota, 25; and West
Virginia, 35. Arkansas reported having reached its cap of 460 and beginning a waiting list. Three applica-
tions had been received; if space was not available for those applicants, they would be the first three on the
waiting list.
Alaska and Colorado re p o rted having capped enrollment or a waiting list but did not participate in 
the interv i e w s .
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GWU researchers interviewed key program staff from each ADAP. The interviews ranged from 45 to 80 min-
utes. Staff were asked a series of 34 open-ended questions about the policies and procedures of their State
ADAPs as they related to methods of controlling enrollment of new clients. Staff were given the opportunity
to share other information not specifically covered by the questions. 
L i m i t a t i o n s
Two States with capped enrollments or waiting lists did not participate in the interview. It is unclear to what
extent the characteristics of their capped enrollment programs or waiting lists differ from those used by
responding ADAPs. 
Major Findings and Discussion
ADAPs’ decisions to cap enrollment are based on attempts to forecast demand and costs as well as on close
monitoring of ongoing expenditures. ADAPs with capped enrollments or waiting lists, however, then rely on
“back-of-the-envelope” forecasting approaches, finding other available tools too cumbersome.
All ADAPs reported that the primary factor causing capped enrollment policies was a combination of
increased costs and increased demand for services. Administrative and political factors (at the State level)
were not seen as significant contributors to the cap. Common factors resulting in capped enrollment
included increased applications for ADAP enrollment; increased rates of utilization of medication on the for-
mulary among ADAP clients; lower rates of people enrolling in the Supplemental Security Income (SSI)
Program and Medicaid; longer duration of enrollment among ADAP clients; and rising medication costs.
Reduced State funding or State funding that did not keep pace with programmatic expenditures of ADAPs
aggravated all those factors.
All but three ADAPs re p o rted that their cap applies to the entire ADAP form u l a ry. Three ADAPs have a sep-
arate cap on a specific medication (Fuzeon). 
All ADAPs reported estimating expenditures per enrollee as a basis for setting the enrollment cap at the
beginning of a fiscal year. They use three variables for this forecast: average expenditures, total number of
enrollees and applicants, and total available funds. Two ADAPs also estimate future medication costs.
ADAPs reported that current tools provided by HAB to forecast expenditures are difficult to use and not
more informative than using the simple formula described. 
All ADAPs monitor expenditures and utilization to determine when capped enrollment must be enforced.
Eleven ADAPs monitor the data monthly, two monitor the data weekly, and one State monitors the data
every other month. All ADAPs reported that the determination of the cap and level of the cap is based exclu-
sively on the amount of funds available at the time the determination is made. ADAPs reported keeping data
mostly in the form of Excel spreadsheets that are updated by ADAP staff. 
All ADAPs reported similar processes in operationalizing capped enrollment. ADAPs begin by disseminating
information about the cap to various constituencies. On the government level, States reported requesting
additional State funding for the ADAP as a starting point for making State legislators aware of the situation.
Only one ADAP reported receiving additional dollars. Several ADAPs have approached their Title I pro-
grams and received funding or other support. ADAPs use several avenues (e.g., statewide planning groups,
a governor’s advisory council, regular meetings with State legislators, and health department administrators)
to increase public awareness of the ADAP and its needs. 
ADAPs reported consultations with various officials and groups regarding development and implementation
of capped enrollment. These include community advisory boards; scientific, clinical, and medical advisory
groups; community planning boards; health department directors and administrators; and program and
financial staff. 
ADAPs define capped enrollment diff e rently; most ADAPs have established a “hard” cap—setting a maxi-
mum number of enrollees who can be permitted in the program. Others have created a “rolling” cap that
adjusts to demand on a monthly basis.
“Capped enrollment” generally meant that an ADAP had determined a set number of enrollees that could par-
ticipate in the program; several States reported having “rolling” caps, a limit of enrollees in the program that
changes throughout the year based on available funding and program costs. For example, one ADAP caps
annual enrollment at 200 clients. This number does not change throughout the year. Another ADAP has a
rolling cap, currently set at 135, which changes as program staff evaluate program utilization from the past
month and add clients as funding allows. For ADAPs with rolling caps, capped enrollment is based on avail-
able funding, so no set number is determined.
Eleven of the interviewed ADAPs reported capping the number of clients that are enrolled in the program.
The cap ranged from 70 clients to 1,250 clients. Five ADAPs reported hard caps that had been exceeded.
Four ADAPs reported rolling caps that were at capacity. One ADAP reported having set a hard cap but not
having reached the number, and one ADAP reported its cap as a monetary cap of $1,200 per client per
month, which had been exceeded. (This ADAP had no cap on the number of clients.)
Given underlying variability in available re s o u rces and, thus, variability in eligibility re q u i rements (Ta b l e
4), ADAPs cap enrollment at diff e rent levels. Because ADAPs are given flexibility in determining eligibili-
ty criteria (including income levels) for the program, an applicant at a certain income level might be wait-
listed in one State and not in another.
ADAPs vary in the steps taken to contain costs prior to imposing capped enrollment. All ADAPs have con-
sidered a standard set of cost-containment measures (e.g., reduced formulary, change in eligibility rules, use
of 340B pricing, use of ADAP Task Force negotiated prices, back-billing third-party payers, and imposition
of client co-payments), but no standardized approach to cost-containment yet exists.
All ADAPs reported having used other budget control measures before implementing capped enrollment.
Those measures include using a reduced formulary (3 States); changing the eligibility rules (2 States), using
340B pricing (7 States), using ADAP Task Force contracts (11 States), and back-billing Medicaid and other
sources (3 States). Several ADAPs specifically mentioned ruling out several of these options, most commonly
the reduced formulary, client copays, and lowering the income eligibility as a percentage of Federal Poverty
Level (FPL). At least in some cases, the ADAP determined that the cost savings were insufficient to be worth
the change in policy. For a full discussion of the policy opportunities in this area, see GWU’s earlier report
prepared under this Task Order, The AIDS Drug Assistance Program: Assessing the Use and Distribution of Scarce
Resources, submitted to HAB in May 2004.
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Most ADAPs maintain waiting lists. ADAPs, even those not maintaining formal waiting lists, continue to
receive and process new applications to determine program eligibility. 
In all the ADAPs interviewed, case managers continue to take and forward applications for the program after
the cap has been reached. Applications are sent to the ADAP staff where they are either held until a slot
becomes available or the person is put on an official waiting list. Case managers trained to provide assis-
tance to clients through other programs, primarily patient assistance programs established by the pharma-
ceutical companies. Case managers are updated regularly (usually monthly) on the status of clients on wait-
ing lists. Clients are informed by letter regarding their status. All ADAPs provide this letter to clients. A copy
of the letter is usually sent to the case manager. Information on the client (e.g., updating of address, current
medical status) is maintained by the case managers at the organization level.
All ADAPs that maintain waiting lists determine client eligibility for the ADAP before placing them on the
waiting list. The level of review of the applications varies for ADAP enrollment in general. For example,
some States do not re q u i re proof of Medicaid denial or State re s i d e n c y, only statements to that eff e c t .
Variation also occurs in how frequently people on the waiting lists are re c e rtified for eligibility in the pro-
gram, though this generally follows the pro g r a m ’s criteria for re c e rtification. 
Table 4. ADAP Eligibility Requirements
Household, Medicaid 
Family, or Denial Letter,
Federal Poverty Individual Require Application, 
State Level % Income Income Asset Limits No Insurance or None
Alabama 250 Gross H N Y A
Alabama 250 Gross H N Y A
Arkansas 300 Gross H N N DL
Idaho 200 Gross F N Y A
Iowa 200 Gross F Y N A
Kentucky 300 Gross H N N DL
Montana 330 Net F N N DL
North Carolina 125 Net F N N A
South Dakota 300 Gross H N N A
West Virginia 250 Gross F N N DL
Indiana 300 Gross H N N DL
Oklahoma 200 Gross F N N DL
Massachusetts $50,000/yr Gross I N N DL
and $2,900/
dependent
Missouri 300 Gross I N N A
New Mexico 300 Gross F N N N
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Data collected vary from State to State. ADAPs re p o rted using the following data to determine eligibility and add
the applicant to the waiting list: FPL (12 States), residency re q u i rement (12 States), Medicaid denial (7 States),
no insurance (2 States), and asset limits (1 State). All ADAPs verify eligibility at the ADAP programmatic level
after receiving the applications. Providing proof of re s i d e n c y, Medicaid denial, etc., varies. Some ADAPs re q u i re
documentation, while others do not. 
All ADAPs regularly review the status of current clients to determine whether a slot can be opened for some-
one on the waiting list.
Variability exists in how ADAPs make room for applicants to be moved from the waiting list. All ADAPs use
recertification (meeting the criteria set by the ADAP to be eligible for the program) to open slots. Twelve
ADAPs reported that they conduct recertification yearly, two ADAPs reported that they recertify every 6
months, and one ADAP reported recertifying every month. Eight ADAPs recertify applicants on the waiting
list before they are placed on the program, unless they have been on the list less than 4 months (on aver-
age). Several ADAPs move clients off the program if they have not filled prescriptions in 90 days or more
(unless documentation of a drug holiday is on file), and a few ADAPs remove applicants from the waiting
list who move to a Title I EMA that covers medications.
C o o rdination between ADAPs and Medicaid programs varies. Some ADAPs have excellent working re l a-
tionships, including online access to Medicaid eligibility verification systems; other ADAPs have essentially
no working relationship with the Medicaid program, even with re g a rd to eligibility determ i n a t i o n .
ADAPs reported the following approaches to coordination with State Medicaid programs: access to online
eligibility database (five States), access to phone eligibility database (five States), regular meetings with
Medicaid staff (three States), and meetings at the case manager level (one State). Four ADAPs reported no
coordination or contact. Some ADAPs reported a positive and highly interactive relationship with their
Medicaid program, whereas others reported a poor, almost adversarial relationship with their Medicaid
counterparts. Personal relationships provide the best hope for strong program coordination, but with
strained Medicaid budgets, these relationships were not always helpful in coordinating programs. 
No ADAP reported coordination between ADAP staff and the Social Security Administration (SSA) in deter-
mining SSI eligibility. Seven ADAPs reported this coordination as taking place at the case management level,
although most reported that such coordination depends on personal relationships between case managers
and SSA staff.
Clients on waiting lists receive varying levels of support in enrolling in pharmaceutical company patient
assistance programs (APAs). Case managers have had a variety of levels of training and experience with
this usually complex process, which re q u i res diff e rent application forms for each pharmaceutical company.
All ADAPs reported having processes (although not written policies) for assisting clients in finding other
sources of medications while on the waiting list. All reported that case managers are trained to assist clients
in accessing APAs and are responsible for helping the client fill out the applications. Two ADAPs reported
that clinics provide assistance in filling out applications for the programs. All reported that the APA appli-
cation process is cumbersome because each pharmaceutical company has its own application process and
most clients must apply to more than one company to cover their drug regimen.
Most waiting list policies and pro c e d u res are not in writing, and the process for their development is not
always transparent. Many ADAPs acknowledged that the lack of written policies and pro c e d u res for the
management of waiting lists, including criteria for transitioning applicants off waiting lists to enro l l m e n t ,
has created challenges in terms of “institutional memory.” Given ADAP staff turn o v e r, the absence of doc-
umentation diminishes continuity of programmatic operations. Although all ADAPs consult with outside
e x p e rts in determining capped enrollment and waiting list protocols, it is unclear that consistent consumer
involvement is part of their development.
ADAPs reported enacting caps as early as December 1997 and as late as May 2004. Most States enacted their
caps in late FY 2002 and FY 2003. Several ADAPs reported seeing a spike in utilization and enrollment in
late FY 2003 but were unable to determine the reason for the spike.
ADAPs were asked how providers, pharmacies, case managers, and clients are informed about the existence
of a cap for their ADAP. The strongest link is between providers and ADAP staff: Most ADAPs reported that
providers are contacted by telephone. Some ADAPs also use letters and emails or faxes to provide informa-
tion. All ADAPs inform the providers (i.e., individual providers, agencies, organizations) of the cap. Several
ADAPs have a centralized pharmacy, so they provide the information in person or by telephone, email, or
fax. ADAPS that have reimbursement programs (through various pharmacies) reported that they provide a
letter or, in the case of five ADAPs, that they do not inform the pharmacy that they have a cap on ADAP
enrollment. 
All ADAPs inform the case managers, primarily by telephone (but also by letter, fax, or email), that a cap is
in place. Most ADAPs inform the case managers about the ceiling number of ADAP clients, the status of the
cap, and the likelihood that the cap will be exceeded and that clients will have to wait for services. ADAPs
indicated that this is the most important relationship of the three—relying on the case managers to provide
information directly to clients. Because ADAPs are aware of the names of ADAP clients’ case managers and
because the number of case managers is relatively small, information about the status of the ADAP is usu-
ally accurate and up-to-date.
All ADAPs rely on case managers to provide information to clients regarding capped enrollment. However,
most clients are not informed unless they are placed on a waiting list. Most communities have consumer
groups that are informed of issues, including capped enrollment and waiting lists, through regular meetings
or other correspondence. But ADAPs reported that this information does not always get disseminated in a
way that informs potential applicants. ADAPs reported that the same communication mechanisms that are
used to announce the cap are used to inform providers, pharmacies, case managers, and clients when the
cap has been lifted.
Two ADAPs reported that they have written policies and procedures on program caps (rationale, design,
implementation, operationalizing, and maintenance). Two ADAPs reported written policies and procedures
in development. All other ADAPs reported that they have no written policies and procedures, although pro-
gram staff had developed internal protocols and procedures. Some ADAPs recognized this as problematic
because loss of staff could cause loss of institutional knowledge about how the cap was developed and is
operationalized.
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Four ADAPs reported that they have written guidelines for their waiting list. Six ADAPs reported that they
have no written guidelines, and four reported that they are in process of writing guidelines. These guide-
lines cover the process of managing the list, determining how applicants are placed on the list and removed
from it, and providing assistance to applicants while they are on the list.
Eleven ADAPs reported relying on case managers to gather information about applicants being placed on
the waiting list (completing the application and maintaining contact information). The case managers fill out
the information and keep the client informed about movement of applicants on the list. Six ADAPs reported
that ADAP staff also collect information on the applicants. No ADAPs reported that providers are involved
in collecting information.
Criteria for moving applicants off waiting lists vary by ADAP. Some ADAPs use a strict “first come, first
s e rved” approach; others use a medical need approach (e.g., pregnant women, those with severely compro-
mised immune systems) or a combination of the two. Most ADAPs move applicants from the waiting list to
ADAP enrollment as slots become available, although at least one ADAP re p o rted waits for enough slots to
open up to move the entire waiting list at one time.
All ADAPs with waiting lists reported that they manage the waiting list at the ADAP programmatic level.
Priority for placement on the list was reported as follows: first come, first served (nine States); medical need
(six States); pregnant women (two States); those already on medications (two States) and, those that are non-
EMA clients (two States). A few ADAPs list first come, first served as their priority, but actually bump clients
with medical need to the top then prioritize by first come, first served.
Priority determination was developed in various ways: Program staff developed the guidelines; ADAP staff
talked to each other to determine the best priority list; medical advisory boards were convened to determine
the priority list; standing clinical care committees or ethics committees were used to determine the priority
list; clinical advisory boards were used to set medical eligibility criteria for priority; and other methods were
used. Most ADAPs did not include consumers in determining priority lists.
ADAPs reported simple policies and procedures for moving applicants off the waiting list. For example,
when a space (or spaces) become available, the person (or group) of persons is moved off the list. However,
some ADAPs wait until they have enough slots available to move all applicants off the waiting list at one
time. Other ADAPs move applicants off the waiting list one at a time. Both clients and case managers are
notified by letter.
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Recommendations and Policy Considerations
Establish minimum cost-containment standards for ADAPs. 
This study demonstrated that some variation exists in the use of cost-containment measures by State ADAPs.
HAB could establish as a condition of award that all State ADAPs demonstrate that they have undertaken a
minimum set of cost-containment strategies, including the following:
+ Regular review of clients for continued eligibility for ADAP or other programs (e.g., Medicaid)
+ Recertification every 6 months to assess eligibility for entitlement, other discretionary programs, and
other third-party benefits
+ Closer coordination with other sources of payment for drugs, such as assistance with application for VA
or Medicaid benefits.
E n s u re that all ADAPs are able to monitor their programs eff e c t i v e l y. 
In working with HAB and State ADAP staff to conduct this and other recent studies, GWU staff identified the
need for ongoing technical assistance (TA) among State ADAP staff in the management and analysis of their
b u d g e t a ry, enrollment, utilization, and claims data. The increasingly complex information re q u i rements of
many State ADAPs has presented a challenge to State ADAP staff in managing and analyzing their data.
E n s u re that all Title I–funded APAs are coordinated with ADAPs and are maximizing the use of re s o u rces. 
The study found variation in the level of coordination between APAs and ADAPs. Additionally, APAs did not
adopt many of the cost-containment strategies common among ADAPs. HAB might adopt the following con-
ditions for Title I award for funding of APAs: 
+ Require coordination in eligibility and formularies with the State ADAPs.
+ Require that APAs follow the same eligibility determination procedures as ADAPs (e.g., regular income
determination and review, regular review for Medicaid eligibility).
+ Require that APAs participate in the 340B program or demonstrate that they are able to achieve a better
price discount than that available under the 340B program or that achieved by the State ADAP (which-
ever is greater).
+ Require that the APA demonstrate that a separately administered program is more cost-effective than
contracting with the State ADAP to provide benefits to Title I clients.
Adapt criteria for ADAP supplemental funding eligibility to accurately reflect current funding deficits.
The study demonstrated that certain ADAP programmatic elements could be changed to improve access to
the program and to ensure that supplemental funds target those State ADAPs that face shortfalls in funding.
As discussed in the report, the following are among the policy options that might be considered:
+ Eliminate the requirement for a separate cash ADAP supplemental match or permit HAB to use the same
criteria as for the match in the underlying Title II award (i.e., in-kind contributions).
+ Require all recipients to follow standard cost-containment strategies (e.g., 340B discount, regular review
of Medicaid eligibility)
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+ I n c rease the percentage set-aside for the supplemental to permit distribution of more funds to States in need
+ Take a new “snapshot” for determining eligibility because some State governments facing difficulties are
not currently eligible using the FY 2000 “snapshot”.
+ Permit HAB to distribute supplemental funds based on need rather than on a case-based formula.
Consider a national “minimum” standard for State ADAPs. 
The steps recommended above would accomplish an important goal of maximizing the purchasing power
of existing ADAP funds based on their current method of distribution. Without a substantial increase in
ADAP funding, however, these steps likely will not be able to address the fundamental issue at hand: the
significant geographic disparity in access to HIV-related treatments under the CARE Act.
One option would be to adopt a “needs-based” formula for distribution of ADAP funds. The formula would
require consideration of various factors, including the number of HIV-infected people who might be
enrolled, the income levels of PLWH, the relative generosity of a State’s Medicaid and other safety-net pro-
grams, and the accessibility of private insurance. Reaching consensus on what elements might establish
“need” would be challenging. Indeed, the Institute of Medicine in its recent report noted that such formu-
las are difficult to develop. It is unlikely that sufficient data exist to develop such a formula.1 As noted ear-
lier, the fiscal and programmatic climate surrounding ADAPs is constantly shifting. Thus, it is unclear
whether formulas could be sufficiently flexible to reflect these changes. Finally, if such an approach resulted
in significant shifts in funding, to avoid disruption in services to current clients, hold-harmless provisions
may be required. As a result, few, if any, changes in distribution of funds will address the issues, absent a
major increase in Federal budget allocations to ADAP.
GWU believes that the problem of geographic inequity cannot be addressed without totally overhauling the
health care financing system of which the CARE Act is just one small part. Indeed, the structure of the
national health care financing system is geared toward leaving to the States the determination of how gen-
erous their publicly funded safety net will be, as reflected in State-by-State variation in Medicaid. 
As is also reflected in the Medicaid program, however, a precedent exists for establishing a minimum level
of eligibility and services to be provided to poor people in need of health care. Applying that concept to
ADAP, and to the CARE Act more generally, is possible by establishing a minimum level of eligibility for a
core set of services for persons with HIV. Although the data probably are not sufficient to determine whether
such a minimum standard could be achieved nationally based on current funding allocation formulas, this
minimum standard could be defined by HAB. A consensus process could be undertaken involving HAB,
grantees, consumers, ethicists, and other key experts to establish a minimum core set of services. Grantees
could be required to achieve this goal to the degree resources permit.
In the very specific context of ADAP, HAB could establish a minimum formulary to be provided to all per-
sons with HIV without other third-party payers who are at or below 200 percent of FPL or another agreed-
upon level. A sliding scale of eligibility above 200 percent of FPL could also be established if deemed fiscally
possible. If the ADAP can meet this standard, it would be free to expand its formulary or income eligibility
levels with its current resources. Such resources might include non-Federal ADAP funds, such as State or
local funds or transfers from other parts of the CARE Act. ADAP supplemental funds could be awarded to
those State ADAPs that maintain their prior funding efforts and cannot meet the minimum standard with
their formula award.
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This approach to ADAP funding could be incorporated into a larger effort to establish a “core” set of services
under Titles I and II of the CARE Act. Presumably, HIV-related medications would be part of any core set of
services. In this instance, States and Title I entities might be required to coordinate and ensure that all core
services are met for individuals below a certain FPL and without other third-party coverage for medications
and other services. Title I and Title II grantees might then be required to transfer some of their grant funds
to ADAPs to help reach this minimum level of service. In this scenario, the “supplemental” portion of Title
I grants and ADAP supplemental awards might be used to assist jurisdictions unable to meet the national
minimum of eligibility for core services.
GWU recognizes that this approach would be a fundamental shift in the philosophy of allocation of
resources and flexibility given to grantees. As resources become more constrained at the Federal, State, and
local levels, however, establishment of a Federal floor for HIV funding would be consistent with the man-
agement of other poverty-based health care financing programs.
Based on currently available data, it is not possible to determine the impact of a change to this approach.
GWU believes this might be a useful avenue for research to determine both its practical applicability and its
impact on access to HIV-related pharmaceuticals by HIV-positive clients.
Consider establishing consistent policies across State ADAPs.
The approaches taken by ADAPs to cap enrollment and institute and manage waiting lists vary significantly.
These differences reflect the larger variations in ADAP approaches noted in GWU’s early studies for HAB.
Although current fiscal challenges do not permit the elimination of this geographic variation, the creation
of ADAP waiting lists is an overt form of rationing access to potentially life-saving medications. Thus, HAB
is obligated to ensure that all effective mechanisms are adopted to avoid waiting lists and that applicants
placed on waiting lists are treated similarly across the country. To that end, HAB could assist ADAPs in the
following ways:
+ Provide TA to ADAPs regarding forecasting costs and triggering of capped enrollment. ADAPs reported that
currently available forecasting tools are cumbersome and difficult to use. New, user-friendly methodolo-
gies should be developed to assist States in this difficult task and to ensure that capped enrollment is
triggered only when absolutely necessary.
+ Work with the Centers for Medicare and Medicaid Services (CMS) to re q u i re that State Medicaid programs coop-
erate with ADAPs re g a rding eligibility determination, coordination of benefits, and cost re c o v e ry by ADAPs.
+ Provide support to ADAPs to develop ongoing training program for case managers to assist clients with access-
ing non-ADAP sources for drugs, particularly through APAs and the VA.
+ Work with the pharmaceutical industry to standardize applications for APAs.
+ Establish Title II program guidance requiring minimum cost-containment efforts as a condition of ADAP awards
(e.g., 340B price or better; implementation of cost-sharing requirements in the CARE Act; policies and
procedures for retrospective billing of third-party insurers; minimum frequency of eligibility recertifica-
tion of clients; re-determination of applicants on the waiting list) to ensure that capping enrollment is a
last resort.
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+ Work with ADAPs, consumer and community representatives, and ethicists to develop national recommendations
for prioritizing waiting lists (e.g., date of application vs. medical criteria). When formal rationing occurs,
the need for a national standard that is transparently arrived at is particularly strong, even if ADAPs ulti-
mately adapt them to local needs.
+ Require ADAPs to have written policies regarding capped enrollment and waiting lists, including a transparent
process for policy development that includes consumer representation. Consumer involvement in determining
rationing strategies is an ethical obligation that is consistent with the underlying philosophy of the CARE
Act. These policies should be reviewed by HAB staff on a routine basis to ensure that critical elements
are in place to ensure sound fiscal stewardship of ADAP funds and optimized access to medications.
1 Institute of Medicine. Measuring What Matters: Allocation, Planning, and Quality Assessment for the Ryan White CARE Act. Washington,
DC: National Academy of Sciences; 2003.
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